The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) and Takeda. The supporters have no influence over the production of the content.
Welcome to The Indolent B-Cell Lymphoma Channel
VJHemOnc brings you the most exciting research, directly from the experts. The Indolent B-Cell Lymphoma Channel covers all of the latest updates presented at major international congresses in the form of video interviews, podcasts and roundtable discussions.
Alongside updates from key clinical trials of CAR-T therapies, monoclonal antibody therapies and BTK inhibitors across the spectrum of indolent B-cell lymphomas, including follicular lymphoma, Waldenström’s macroglobulinemia and more, The Indolent B-Cell Lymphoma Channel covers advances in therapy optimization, the management of therapy-related toxicities and the latest findings from real-world data studies.